Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24162066 | 0.84 | KMT2A (0.43) | OPRM1SLC6A4SLC6A3SLC6A2KMT2A | |
| SCHEMBL5953333 | 0.69 | NPSR1 (0.41) | OPRM1SLC6A4SLC6A3SLC6A2KMT2A | |
| SCHEMBL24310259 | 0.68 | KMT2A (0.43) | OPRM1SLC6A4SLC6A3SLC6A2KMT2A | |
| SCHEMBL24309156 | 0.67 | MEN1 (0.42) | OPRM1KMT2A | |
| SCHEMBL27511149 | 0.66 | OPRM1 (0.51) | OPRM1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL24596435 | 0.63 | OPRL1 (0.43) | SLC6A4KMT2APKM | |
| SCHEMBL11473213 | 0.63 | SLC18A3 (0.40) | OPRM1SLC6A4KMT2A | |
| SCHEMBL24596440 | 0.62 | POLB (0.44) | OPRM1SLC6A3 | |
| SCHEMBL22147811 | 0.62 | MMP1 (0.51) | OPRM1KMT2A | |
| SCHEMBL9438522 | 0.62 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-07 | — | — | US | disclosed |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | OPRM1 1130/4885SLC6A4 4063/4885SLC6A3 4107/4885 |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | OPRM1 1130/4885SLC6A4 4063/4885SLC6A3 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.